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ABSTRACT 
 
 
Multiple sclerosis (MS) is an inflammatory disease characterized by damage to 
neuronal fatty myelin sheaths and neuronal dysfunction. Studies have shown that 
transgenic mice expressing a T-cell receptor (TCR) reactive to GFAP can succumb to 
spontaneous autoimmunity with pathologies comparable to MS. This study focused on 
the expression of a MHC-I type H2-Db β-2m receptor domain in pBac & cloning H2-Db 
into a pLM-1 expression vector.  The β-2m domain expression vector was transformed 
into BL21 cells, and expression was confirmed via SDS-PAGE. The H2-Db genes were 
then successfully cloned into the pLM-1 expression vector. Successful expression of β-
2m receptor domain and of H2-Db/GFAP ligand complex will be used for further 
experimentation to observe abnormalities within the H2-Db epitope and its role in MS. 
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BACKGROUND 
 
Multiple Sclerosis (MS) is the most common neurological disease in young adults 
with a prevalence of over one million.  It is an inflammatory disease, commonly 
described as autoimmune encephalomyelitis, that targets the central nervous system 
(CNS) characterized by damage to neuronal fatty myelin sheaths and neuronal 
dysfunction resulting in white and grey matter lesions (Huseby, 2012). Active lesions, 
which form focal demyelinating plaques, are predominantly composed of self-reactive T- 
cells, activated macrophages, and microglia that escape negative selection resulting in 
neurological degradation.  This degradation disrupts the transmission of nerve signals 
from the spinal cord and brain to other parts of the body resulting in the primary 
symptoms of MS patients (hyperreflexia, ataxia, spasticity, and visual defects) which 
vary depending on the damage incurred (Huseby, 2012).   
Symptoms variance plays a discrete role in the presentation of four main disease 
course pathologies. The disease course can be relapsing-remitting, primary-progressive, 
secondary-progressive, and progressive relapsing (Society, 2013).   Relapsing remitting 
disease occurs in approximately 85% of MS patients who experience defined attacks of 
neurological function. These relapses are often followed by periods of remission during 
which no disease progression takes place (Society, 2013).  The second course of disease 
progression is primary-progressive where MS patients show slow degeneration of 
neurological function with no distinct remissions.  The rate of progression for this course 
of the disease varies over time and contains temporary plateaus with temporary minor 
improvements (Society, 2013).  The third disease course is secondary-progressive. This 
disease course often follows an initial relapsing-remitting disease course.  At this stage 
  6 
many patients experience a steady disease progression with no occasional flare-ups or 
remissions (Society, 2013).   The last disease course is progressive relapsing. This course 
affects approximately 5% of all MS patients and is characterized by a steadily increased 
disease rate from the beginning with clear neurological degrading attacks.   Autoimmune T-cell Responses  
Multiple Sclerosis is hypothesized to be caused, in part, by autoimmune T-cell 
responses directed against antigens of the CNS (McFarland & Martin, 2007; Steinman, 
2009).  Following exposure to environmental triggers, myelin specific T-cells, specific 
for myelin basic protein (MBP), myelin associated glycoprotein (MAG), proteolipid 
protein (PLP), and myelin oligodendrocyte glycoprotein (MOG), become activated and 
are able to escape negative selection  (Sospedra & Martin, 2005; Governman, 2009). This 
activation allows T cells to cross the blood brain barrier (BBB) and interact with myelin 
antigen triggers on antigen-presenting cells (APCs) of the CNS. Reactivation of T-cells in 
this manner recruits cells of the innate immune system, which then play a role in 
mediating axonal damage and demyelination resulting in CNS inflammation and plaque 
formation (Goverman, 2009).   In order for CD4+ T-cells and CD8+ T-cells to initiate 
CNS inflammation they must first infiltrate the CNS from the periphery.  
CD4+ mediated T-cell infiltration and inflammation begins with the priming by 
dendritic cells presenting myelin/ myelin cross-reactive epitopes (Figure 1). These myelin 
antigens can then be captured by antigen presenting cells of the CNS resulting in the 
migration across the cervical lymph nodes (Goverman, 2009).  Local APCs can also 
phagocytize soluble myelin antigens which drain from the CNS to the lymph nodes.  
After T cell priming, CD4+ T cells cross the blood cerebrospinal fluid barrier via the 
choroid plexus or the meningeal venules. This then allows for these T cells to enter the 
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Figure 1: Activation of Myelin-Specific CD4+ T-Cells (Goverman, 2009) 
subarachnoid space (Goverman, 2009).  Once in the subarachnoid space, MHC Class II 
expressing macrophages and dendritic cells containing myelin epitopes, re-activate T-
cells (Figure 1).    
These cells then activate microglial cells triggering the activation of other, distal 
microglial cells and blood vessels (Goverman, 2009).  Activated CD4+ T-cells are then 
able to adhere to the blood-brain barrier and enter the perivascular space (Figure 1). They 
are then reactivated by perivascular dendritic cells and macrophages.  
The re-activation of these self-reactive CD4+ T cells then results in the targeting 
of CNS proteins, such as MBP and PLP  (Sospedra & Martin, 2005; Governman, 2009). 
Disease causing myelin specific CD4+ T cells release Th1 and Th17 cytokines, which 
cause an increase in major histocompatibility complex (MHC) expression within the 
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CNS.  MHC expression then leads to the activation of microglia and further recruitment 
of monocytes and other T cells to the site of inflammation.  Cytokines released during 
this inflammatory response, include IFNγ, TNFα, IL-6, IL-2, and IL-23, and are common 
soluble mediators (Tsuchida et al., 1994).  These mediators result in the demyelination of 
neuronal cells and as such have been associated with the pathogenicity of the disease 
(Jurewicz et al., 1998; Medana et al., 2001).  
Along with CD4+ T cells, CD8 + T-cells also play a role in the pathogenicity of 
the disease. CD8+ T cells are also specific for CNS proteins such as MBP, MAG, and 
PLP (Huseby, 2012). These cells infiltrate the central nervous system in a similar way 
than CD4 cells except that CD8+ T cells are activated by macrophages, microglial cells, 
and dendritic cells via cross-presentation. CD8+ T-cell cross presentation occurs when 
endothelial cells can directly present the antigen to myelin epitopes (Goverman, 2009).  
Finally self-reactive T-cells enter the parenchyma.  Soluble mediators expressed by 
CD8+ T cells include the pro-inflammatory cytokines IFNγ and TNFα. The expression of 
these cytokines is in response to the presentation of CNS protein epitopes by MHC Class 
I molecules in activated macrophages and microglial cells (Huseby, 2012).  These soluble 
mediators are capable of lysing oligodendrocytes expressing MHC class I and myelin 
epitopes resulting in demyelination of neuronal tissue and contributing to inflammatory 
response (Goverman, 2009).   
Inflammation seen in autoimmune encephalomyelitis (EAE) mediated by these 
MHC Class II and MHC Class I-restricted CD4+ and CD8+ T cells, respectively; result 
in the accumulation and formation of lesions within the white and grey matter regions of 
the brain (Lassman, Wolfgang, & Lucchinetti, 2007). These lesions, characteristic of 
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multiple sclerosis, depict degraded neuronal tissue surrounded by activated T-cells. There 
are several mice models which depict a similar EAE response to MS patients.  
Mice Models for Multiple Sclerosis  
Studies have generated two types of mice models that induce autoimmune 
encephalomyelitis. A commonly used mouse model resulting in EAE is focused upon the 
role of Th1 and Th17 phenotype CD4 T cells (Huseby, 2012).  In this CD4-EAE model, 
TCR transgenic mice were crossed with RAG-1 gene-deficient mice. This cross yielded 
mice capable of expressing a transgenic T cells receptor (TCR) specific for MBP but no 
other lymphocytes (Lafaille et al., 1994). In studies conducted by Lafaille et al., all T/R- 
mice developed spontaneous EAE over a 12 month period.  It was also found that the 
mice incurring spontaneous EAE associated with typical EAE lesions in the central and 
peripheral nervous system.  Furthermore, this mouse model presented MBP-specific T 
cells in the brain but not in the peripheral lymphoid tissues.  This study proved that CD4+ 
anti-MBP T cells are capable of mediating EAE within this mouse model and that 
spontaneous EAE may be triggered by in situ activation of CD4+ anti-MBP cells in the 
nervous system.  
The second type of mouse model focuses primarily on the role of CD8+ T cells in 
autoimmunity. In a study conducted by Huseby et al., C2H MBP -/- and MBP +/+ mice 
were infected with Ad/MBP. Results demonstrated that MBP-specific CD8 T cells are 
subject to immune tolerance. Furthermore, this study showed that the activation of MBP-
specific CD8 T cells in mice resulted in severe demyelinating central nervous system 
autoimmunity (Huseby et al., 2001). Analysis of brain and spinal cord tissue, revealed 
lesions (mostly found in the brain) containing perivascular cuffing with common 
demyelinating and cytoplasmic swelling (Huseby, 2012).  This study demonstrated that 
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viruses are capable of inducing CD8 T cell autoimmunity via the disruption of peripheral 
tolerance mechanisms (Huseby, 2012).  In another study conducted by Fournier and 
colleagues, it was found that C57BL/6 mice over-expressing co-stimulatory CD86 
molecules on peripheral T cells and resident CNS microglia, spontaneously succumbed to 
CD8 T cell-dependent CNS autoimmunity. This study collectively demonstrated that 
spontaneous demyelinating disease as a consequence of inflammatory response is 
initiated via the activation of CNS specific T cells (Brisebois et al., 2006). These mice 
models thereby, demonstrate evidence that supports the hypothesis that auto reactive CD8 
T cells are capable of contributing to the pathogenicity of inflammatory diseases such as 
multiple sclerosis (Brisebois et al., 2006).  Preliminary Data: GFAP264-272 specific T cell responses in BG1 Tg mice 
Recent data has demonstrated the formation of plaques within grey and white 
matter regions indicating that proteins other than myelin may be targeted during the 
progression of MS in patients (Ontaneda, 2011). In order to look into the role of other 
CNS proteins in the pathogenicity of the disease, GFAP (glial fibrillary acidic protein), 
expressed primarily in astrocytes in grey and white matter regions of the brain and spinal 
cord, was examined in a mouse model expression GFAP-specific CD8 T cells. It was 
hypothesized that they immune cells would target grey and white matter regions of the 
CNS resulting in a disease progression similar to MS. To test this hypothesis, TCR 
transgenic mice expressing the Vα4 and Vβ9 chains from GFAP-specific CD8 T cell 
clone BG1. It was found that CD 8 T-cells, reactive to GFAP, can induce central nervous 
system autoimmunity with pathologies similar to multiple sclerosis. BG1 TCR Tg mice 
were also found to develop paralytic disease  with a disease progression resulting in 
mature lesions, demyelination of the cerebellum as well as classical EAE symptoms 
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(infiltration along most of the spinal cord) (Huseby, preliminary unpublished data). 
Furthermore, preliminary data has shown that BG1 TCR Tg mice, which express a TCR 
for GFAP, can succumb to spontaneous autoimmunity. In addition the T-cell repertoire of 
these mice is skewed towards the CD8 T-cell lineage, resulting in GFAP peptides bound 
to the MHC Class I H2-Db molecule (Figure 2A.)  
 
 
 
MHC Class I molecules are composed of two polypeptide chains, α and β-chains. 
The α-chain is covalently bonded to the β-chain, and spans the membrane. The complete 
MHC Class I molecule is comprised of four domains, three formed from the MHC 
encoded α-chain and one encoded from the MHC encoded β2-microglobulin (Murphy, 
2012) The α1 and α2 domains of MHC the Class I molecule compose the peptide binding 
cleft (Figure 3).  
Figure 2: Representation of skewed CD8 T-cell lineage background stained with GFAP MHC Class I 
H2-D
b
/GFAP
264-272
. (Huseby Lab Preliminary (unpublished) Data) 
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Determining the structure of H2-D(b) + GFAP ligand complex will define the 
antigenic epitope,  and could unravel the pathogenicity of the spontaneous autoimmunity 
seen in the  BG1 mice models.   
  
Figure 3: MHC Class I structure (Murphy, 2012) 
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PROJECT PURPOSE 
 
The purpose of this project was to express the β2-microglobulin domain of the 
H2-Db gene, and to clone and express its alpha domain for its future crystallization. The 
MHC Class I H2-Db molecule was selected for crystallization as a direct result of the 
molecule’s presentation of glial fibrillary acidic protein (GFAP).  Studies have shown 
that transgenic mice expressing a T cell receptor (TCR) reactive to GFAP presented H2-
Db can succumb to spontaneous autoimmunity with pathologies comparable to MS. CD8+ 
T-cells, reactive to GFAP, can induce central nervous system autoimmunity with 
pathologies similar to multiple sclerosis.  
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METHODS Expression of β2m H2-Db Domain  
The β-2m receptor domain of MHC Class I H2-Db in a pBac bacterial expression 
vector (Figure 4) was transformed into BL21 E. coli cells.  
 
Figure 4:  Map of the pBac Expression Vector Encoding the D
b
 β2m Domain. 
 
Transformed BL21 cells were then cultured at 37 ̊C overnight in 2x TY medium 
containing 1000x Carbinicillin. 0.5mL of culture were removed from the sample and 
frozen via the addition 200 µL of 80% glycerol.   Isopropyl β-D-thiogalactopyranoside 
(IPTG) was added to 1 mL remaining culture and pre and post-induction cultures were 
incubated for 3 hours at 37 ̊C shaking until a final O.D of 0.6 was achieved.  Cultures 
were then centrifuged and bacterial pellets were boiled in 50 µL 2X SDS sample buffer at 
95 C for 5 minutes.  
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SDS-Gel Assay for β2m H2-Db Domain  
10 µL of the 50 µL samples boiled in 2X SDS sample buffer, were loaded into a 
12% SDS-PAGE gel and run at 200V at 0.3 A for 55 minutes at RT. Gel was then stained 
for 20 minutes using Coomassie Blue. Gel was then subjected to a fast de-stain of 15 
minutes using a 50% methanol, 10% acetic acid. An additional fast de-stain was then 
performed. This was then followed by an overnight slow de-stain composed of 5% 
methanol and 7% acetic acid. 
 Cloning of H2-DbGenes into pLM-1 Expression Vector 
To construct the expression vector for H2-Db , the gene fragment coding for 
amino acids 888-1745 was amplified by polymerase chain reaction (PCR) using the 
oligonucleotides GGGGGGGAATTCATGGGCCCACACTCGATGCG (forward primer 
labeled 5315) & CCCCCCAAGCTTTTACCATCTCAGGGTGAGGGGCTCAGG 
(reverse primer labeled 5299). The PCR reaction mixture consisted of 4uL of 10X PCR 
buffer; 4µ L of dNTP, 4µL of each 10X primer, 1µL of Taq DNA polymerase, and 1µL 
of p3630 plasmid DNA containing H2-Db gene sequence. The PCR cycle consisted of an 
initial denaturing phase at 94°C for 1:00 minutes followed by 30 amplification cycles 
(94°C for 30 seconds, 60°C for 15 seconds, 72°C for 1:50 minute. The reactions were 
held at 4°C until retrieved from the PCR machine.  
4uL of the resulting fragment and 5uL of the pLM-1 expression vector were then 
digested using a 20 L solution containing 1uL EcoRI-HF, 1 µL HindIII, and 2 µL of 10x 
Buffer 2, and 11 and 12µL of ddH2O respectively. The two samples were then incubated 
in a 37°C water bath for one hour. Samples were then run in 2% agarose gel and gene 
cleaned using 10% acetic acid.    
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Ligation was then performed using a ligation mixture of 6µL of H2-Db fragment, 
1 µL of pLM-1 vector, 1.2 µL of 10x T4 Ligase buffer, 1 µL of T4 Ligase, and 3 µL of 
ddH2O. A negative control was also done using a ligation mixture of 6uL of of pLM-1 
vector, 1.2µ L of 10 T4 Ligase buffer, 1 µL of T4 Ligase, and 4 µL of ddH2O. Ligation 
was performed at 16 °C for 18 hours.  
6 µL of ligation and control sample were place into two 14 µL aliquots of E. coli 
competent cells and transformed.  100 µL of 2x TY medium containing 1000x 
Carbinicillin was then added to each aliquot and were allowed to grow overnight on 
Carbinicillin plates. 24 colonies were then selected from the experimental ligation plate 
and  40 µL of 2x TY medium containing 1000x Carbinicillin were added to a 96 well 
plate with one colony per well. These were then incubated for 3.5 hours in 37°C.  PCR 
Screen of E. coli containing pLM-1 Expression Vector Encoding H2-Db was then 
performed using solution containing 1µL of bacterial DNA, 1µL of reverse primer, 1 µL 
of forward primer, 1.5 µL of dNTP, 1.5 µL of 10X PCR Buffer, 0.05 µL of Taq DNA 
polymerase, and 9 µL of ddH2O. The PCR cycle consisted of an initial denaturing phase 
at 94°C for 1:00 minutes followed by 30 amplification cycles (94°C for 30 seconds, 60°C 
for 15 seconds, 72°C for 1:50 minute  
5 colonies, labeled clones 10, 12-15, were then selected and were grown 
overnight in 3mL of 2x TY medium containing 1000x Carbinicillin.  Mini-prep was then 
performed and a spectrophotometer was used to measure DNA concentration in each 
clone. A 1:25 dilution was performed on all samples.  Expression of H2-Db  
Previously screened clones were then transformed into was transformed into BL21 E. coli 
cells and were then incubated on Carbinicillin plates overnight at 37°C. Colonies from 
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each clone (10, 12, 13, 14 and 15) were then PCR screened. The PCR cycle consisted of 
an initial denaturing phase at 94°C for 1:00 minutes followed by 30 amplification cycles 
(94°C for 30 seconds, 60°C for 15 seconds, 72°C for 1:50 minute.  Samples were then 
run on a 2% agarose gel with pLM-1 vector without H2-Db used as a negative control. 
Transformed BL21 cells were then cultured at 37 ̊C overnight in 2x TY medium 
containing 1000x Carbinicillin. 0.5mL of culture were removed from the sample and 
frozen via the addition 200 µL of 80% glycerol.   Isopropyl β-D-thiogalactopyranoside 
(IPTG) was added to 1 mL remaining culture and pre and post-induction cultures were 
incubated for 3 hours at 37 ̊C shaking until a final O.D of 0.6 was achieved.  Cultures 
were then centrifuged and bacterial pellets were boiled in 50 µL 2X SDS sample buffer at 
95 C for 5 minutes.  SDS-Gel Assay for H2-Db   
10 µL of the 50 µL samples boiled in 2X SDS sample buffer, were loaded into a 
12% SDS-PAGE gel and run at 200V at 0.3 A for 55 minutes at RT. Gel was then stained 
for 20 minutes using Coomassie Blue. Gel was then subjected to a fast de-stain of 15 
minutes using a 50% methanol, 10% acetic acid. An additional fast de-stain was then 
performed. This was then followed by an overnight slow de-stain composed of 5% 
methanol and 7% acetic acid. 
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RESULTS 
 
Studies have shown that CD8+ T-cells, reactive to GFAP, can induce central 
nervous system autoimmunity with pathologies similar to multiple sclerosis. MHC Class 
I H2-Db molecule was selected for crystallization as a direct result of the molecule’s 
presentation of glial fibrillary acidic protein (GFAP). The purpose of this project was to 
express the β2-microglobulin domain of the H2-Db as well as to clone and express H2-Db 
α domain for its future crystallization. SDS-PAGE Gel Assay depicts successful Expression of the β2-microglobulin H2-Db Domain 
  First, the β2-microglobulin domain of MHC Class I H2-Db in a pBac bacterial 
expression vector was transformed into BL21 E. coli cells. Transformed BL21 cells were 
then cultured at 37 ̊C overnight in 2x TY + 1000x Carbinicillin, and induced at 0.1M 
IPTG. 
 
 
Figure 5: SDS-PAGE Gel Assay for the Expression of the β2-Microglobulin Domain of MHC Class I. 
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The SDS-PAGE Gel Assay (Figure 5) was performed to confirm the expression of the 
β2-microglobulin domain of the MHC Class I H2-Db molecule. Dark bands in lanes 2, 4, 
6, and 8 at approximately 800 bp depict post-induction clones (1-4) of the β2-
microglobulin demonstrating successful expression. Lanes 1, 3, 5, and 7 depict the pre-
induced clones.  Cloning of H2-DbGenes into pLM-1 Expression Vector 
To construct the expression vector for H2-Db α domain (Figure 6) , the gene 
fragment coding for amino acids 888-1745 was amplified by polymerase chain reaction 
(PCR) using the oligonucleotides GGGGGGGAATTCATGGGCCCACACTCGATGCG 
(forward primer) & CCCCCCAAGCTTTTACCATCTCAGGGTGAGGGGCTCAGG 
(reverse primer).  Both fragment and vector were cut using HindII and EcoRI-HF. The 
resulting expression vector contained the H2-Db gene fragment ligated at 888 bp and 
1745 bp. This expression vector also contained genetic sequence for ampicillin resistance 
(Figure 6).  
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A PCR screening of 24 clones containing the pLM-1 vector with the H2-Db insert was 
then conducted (Figure 7).  Bands at approximately 800 bp, (in lanes 1, 3, 4, 9, 10 12, 13, 
14, 15, 17-19, 20-21) depict the successful cloning of H2-Db into its expression vector 
(Figure 7). 
 
 
 
 
5 colonies, labeled clones 10, 12-15, were then selected from data of PCR screen 
(Figure 7) and were grown overnight in 3mL of 2x TY medium containing 1000x 
Carbinicillin.  Mini-prep was then performed and a spectrophotometer was used to 
measure DNA concentration in each clone (Table 1). 
 
 
Figure 7: PCR Screen of E. coli containing pLM-1 Expression Vector Encoding H2-D
b
.  
  21 
Table 1: DNA concentration of clones 10, 12, 13, 14, 15 (ng/ µL) 
 
Clone Number DNA Concentration ( ng/µL) 
10 334.2 
12 243.7 
13 362.7 
14 364.5 
15 280.4 
 
The results demonstrated high DNA concentrations for clones 10, 13, and 14 of over 300 
ng/ µL. Clones 12 and 15 showed lower concentration at 243.7 ng/ µL and 280.4 ng/ µL 
respectively.  Expression of H2-Db  
DNA from clones 10, 12, 13, 14 and 15 were transformed into BL.21 cells, plasmid DNA 
was isolated and PCR was done for H2-Db (Figure 8).  Lanes 2 through 5 represent 
clonal DNA taken from clones 10, 12, 13, 14, and 15, respectively, with each containing 
a strong band at 800 bp, indicative of H2-Db  Lane 6 represents negative control clonal 
DNA from pLM-1 plasmid vector without H2-Db.  
 
 
 
 
 
 
 
 
 
Figure 8: PCR Screen of Potential Positives Transformed into BL.21 Cells. 
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MHC Class I H2-Db in a pBac bacterial expression vector was transformed into BL21 E. 
coli cells. Transformed BL21 cells were then cultured at 37 ̊C overnight in 2x TY + 
1000x Carbinicillin, and induced at 0.1M IPTG.  The SDS-PAGE Gel Assay (Figure 9) 
was performed to confirm the expression of the MHC Class I H2-Db α domain. Absence 
of bands at approximately 800bp, show that expression of the α domain was 
unsuccessful. Sequencing of clones 10, 12, 13, and 14 resulted in no priming capabilities.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: SDS-PAGE Gel Assay for the Expression of the α H2-Db Domain of MHC I molecule. 
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DISCUSSION 
Studies have shown that transgenic mice expressing a T cell receptor (TCR) 
reactive to glial fibrillary acidic protein presented by the MHC Class I H2-Db molecule 
can succumb to spontaneous autoimmunity with pathologies comparable to Multiple 
Sclerosis (Huseby, preliminary unpublished data).  MHC Class I molecules are composed 
of two polypeptide chains covalently bonded, α and β-chain (Murphy, 2012).  The 
purpose of this project was to express the β2-microglobulin domain of the H2-Db as well 
as to clone and express H2-Db α domain for its future crystallization 
Data collected from PCR screens (Figure 8 and 7) demonstrate a successful 
cloning of H2-Db into the pLM-1 expression vector. These agarose gels depict clones 
containing fragments of size equal to that of H2-Db molecule (~800bp). Large 
concentrations of bacterial DNA taken from these clones (Table 1) further supported the 
success of cloned fragment into the PLM-1 expression vector.  Sequencing for these 
clones, however, revealed a lack of priming. This could have resulted from non-
functional or contaminated primers as well as mutations within the H2-Db containing 
pLM-1 vector.  
Prior to obtaining sequencing results, clones (Table 1) were induced and tested for 
expression.  The induction and expression of these clones proved to be unsuccessful 
(Figure 9).  This could indicate that the H2-Db fragment did not clone successfully into 
the pLM-1 vector or that detrimental mutations within the sequence occurred during 
cloning preventing protein expression. In addition, mutations within the pLM-1 
expression vector could have prevented the successful ligation of an accurate gene 
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sequence. Other possible causes for lack of expression could have resulted from the use 
of non-functional enzymes or contaminated IPTG.  
 Experimental data concerning the β2-microglobulin domain of the MHC Class I 
demonstrated the successful induction and expression (Figure 5). This will then allow for 
the future refolding of the whole refolding of the H2-Db MHC Class I molecule once the 
α domains are successfully expressed.  Following the re-folding, crystallization of this 
MHC molecule bound to the GFAP ligand, seen in BG1 Tg mice, will reveal its structure.  
Structural analysis of MHC Class I H2-Db + GFAP will depict any abnormalities within 
the H2-Db epitope and shed light the molecule’s role in the spontaneous autoimmune 
disease seen in BG1 Tg mice (Huseby, unpublished preliminary data).   
The ability to define the antigenic epitope of the MHC molecule bound to the GFAP 
peptide will determine its pathogenic role and will open ways for production of this 
molecule in ex vivo analysis, in vivo imaging reagents, and in the efficient visualization 
of disease progression within the BG1 Tg mice models and eventually in humans.  
Defining the antigenic epitope of the MHC H2-Db molecule will allow for the 
introduction of retrogenic methods in order to determine the pathogenicity of T cells.  
The determination and defining of molecular targets of these auto reactive T cells will 
then allow for a modulation of this autoimmune response through the use of antigen-
specific therapies. These therapies could then, eventually, prevent the development of this 
autoimmune disease in mice, and eventually in MS patients.  
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